Clarithromycin 500mg (2 Tablets) + Pantoprazole 40mg (2 Tablets) + Amoxycillin 500mg (2 Capsules)
PANSWING™ HP Kit is a complete, pre-packaged H. pylori triple therapy eradication kit containing all three agents required for the globally validated standard triple therapy regimen in a single daily dose pack.
Clarithromycin (500mg × 2 tablets/day): A macrolide antibiotic that inhibits H. pylori protein synthesis by binding to the 50S ribosomal subunit, blocking translocation. Clarithromycin achieves high gastric mucosal concentrations and is the macrolide with the highest intrinsic anti-H. pylori activity. The 500mg twice-daily dose is the guideline-specified dose for H. pylori eradication — lower doses show significantly reduced eradication rates.
Amoxycillin (500mg × 2 capsules/day = 1g twice daily): A broad-spectrum penicillin that kills H. pylori by inhibiting PBP-mediated peptidoglycan synthesis. Amoxycillin in combination with clarithromycin provides synergistic H. pylori bactericidal activity — clarithromycin inhibits protein synthesis while amoxycillin attacks cell wall integrity simultaneously, reducing resistance emergence.
Pantoprazole (40mg × 2 tablets/day): A proton pump inhibitor that irreversibly inhibits H⁺/K⁺-ATPase on the gastric parietal cell, suppressing acid secretion. Acid suppression is not merely symptomatic — it is pharmacologically essential for H. pylori eradication. At low gastric pH (below 4), H. pylori enters a non-replicating state where antibiotics are less effective. By raising intragastric pH above 5, pantoprazole ensures H. pylori remains in the metabolically active, replicating state where antibiotics achieve bactericidal concentrations. PPI co-administration also increases clarithromycin and amoxycillin mucosal concentrations by reducing gastric fluid volume.
PANSWING™ HP Kit is specifically designed for H. pylori eradication — the treatment of the bacterial infection responsible for the majority of peptic ulcer disease and gastric carcinoma.
H. pylori Eradication (Primary Indication): Standard triple therapy (PPI + clarithromycin + amoxycillin) for 14 days achieves eradication rates of 70–85% in clarithromycin-susceptible H. pylori infections. Indicated for all patients with confirmed H. pylori infection by any validated diagnostic test (rapid urease test, urea breath test, stool antigen test, or serology).
Peptic Ulcer Disease: H. pylori eradication is curative for H. pylori-associated duodenal and gastric ulcers — preventing ulcer recurrence in >90% of successfully eradicated patients.
NSAID-Associated Ulcers: H. pylori eradication reduces NSAID-associated ulcer risk and should be performed before initiating long-term NSAID therapy.
Gastric MALT Lymphoma (Early Stage): H. pylori eradication induces complete remission in a significant proportion of early-stage gastric MALT lymphoma cases.
Functional Dyspepsia: Eradication produces sustained symptomatic improvement in approximately 10% of H. pylori-positive functional dyspepsia patients — a modest but real benefit in a condition with few effective interventions.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
H. pylori infection affects over 4 billion people globally — approximately half the world's population — and India's prevalence is particularly high, exceeding 50% in many adult cohorts and higher in lower socioeconomic groups. The causal link between H. pylori and peptic ulcer disease (>95% of duodenal ulcers, 80% of gastric ulcers) means that successful eradication is curative — eliminating the need for long-term acid-suppression therapy and preventing ulcer recurrence.
PANSWING™ HP Kit's pre-packaged format addresses one of the most persistent challenges in H. pylori management — compliance with a multi-drug, twice-daily, 14-day regimen. Studies consistently show that pre-packaged kits achieve higher eradication rates than separately dispensed components, primarily by eliminating the confusion and missed doses inherent in managing three different medicines simultaneously.
The PANSWING™ brand connection — associating the HP Kit with the widely prescribed PANSWING™ LS (Pantoprazole + Levosulpiride) in the Seclis Labs gastrointestinal portfolio — creates brand recognition and recall among gastroenterologists that aids prescribing decisions. For franchise partners, HP eradication kits are high-value, high-volume products with consistent demand from gastroenterology and general medicine OPDs throughout the year.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.